Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care? A narrative systematic review of the evidence base

British Journal of General Practice

Volumn 63, Issue 617, 2013, Pages

  Brew, Iain F ^a   Butt, Christine ^a   Wright, Nat ^a  

^a LEEDS COMMUNITY HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

General practice; Hepatitis C; Pegylated interferon; Primary care; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; OPIATE; PEGINTERFERON; ALPHA INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

ANTIVIRAL THERAPY; GENERAL PRACTICE; GENERAL PRACTITIONER; HEPATITIS C; HUMAN; INTENTION TO TREAT ANALYSIS; MAINTENANCE THERAPY; MEDICAL EDUCATION; MONOTHERAPY; OPIATE SUBSTITUTION TREATMENT; PRIMARY MEDICAL CARE; PSYCHOSOCIAL CARE; REVIEW; SYSTEMATIC REVIEW; TELECONFERENCE; TREATMENT RESPONSE; EPIDEMIOLOGY; HEALTH CARE DELIVERY; HEPATITIS C, CHRONIC; PRIMARY HEALTH CARE; PRISONER; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ANTIVIRAL AGENTS; DELIVERY OF HEALTH CARE; EPIDEMIOLOGIC METHODS; GENERAL PRACTICE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PRIMARY HEALTH CARE; PRISONERS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84888788772     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp13X675421     Document Type: Review

References (34)

1. Health Protection Agency Centre for Infections, Health Protection Scotland, Public Health Wales, Health & Social Care Board Northern Ireland. Hepatitis C in the UK: 2013 report. http://www.hpa.org.uk/Publications/ InfectiousDiseases/BloodBorneInfections/HepatitisCInTheUK/ 1307HepatitisCintheUK2013report/ (accessed 3 Nov 2013).
2. World Health Organization. Hepatitis C. Fact Sheet 164. 2013. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 3 Nov 2013).
3. Jowett SL, Agarwal K, Smith BC, et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001; 94(3): 153-158.
4. Zevin B. Managing chronic hepatitis C in primary care settings: more than antiviral therapy. Public Health Reports 2007; 2 (122 Suppl): S78-S82.
5. Skipper C, Guy JM, Parkes J, et al. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003; 52: 1500-1504.
6. Scott, DL, Symmons DPM. The role of specialists in managing established rheumatoid arthritis. Rheumatology 2008; 47(3): 237-238.
7. Kivlahan C, Chavey W. What are the current treatment and monitoring recommendations for hepatitis C virus (HCV). J Fam Pract 2001; 50(11): 928-929.
8. Budd J, Robertson R. Hepatitis C and general practice: the crucial role of primary care in stemming the epidemic. Br J Gen Pract 2005; 55(513): 259-260.
9. Gardenier D, Alfandre D. Primary care of the patient with chronic hepatitis C. J Nurse Pract 2006; 2(8): 517-524.
10. Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 5 (40 Suppl): S276-S285.
11. Royal College of General Practitioners and Health Protection Agency. RCGP Certificate in the Detection, Diagnosis and Management of Hepatitis B and C in Primary Care Part 2 Programme Handbook. London: RCGP, 2012.
12. Strang J, Sheridan J, Hunt C, et al. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. Br J Gen Pract 2005; 55(515): 444-451.
13. Department of Health. Hepatitis C: Essential information for professionals and guidance on testing. London: DoH, 2004.
14. Royal College of General Practitioners. Guidance for the prevention, testing, treatment and management of hepatitis C in primary care. 1st edn. London: RCGP, 2007.
15. Hill WD, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol 2008; 22(1): 27-32.
16. John-Baptiste A, Varenbut M, Lingley M, et al. Treatment of hepatitis C infection for current or former substance abusers in a community setting. J Viral Hepat 2009; 16(8): 557-567.
17. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18(5): 437-443.
18. Newman AJ, Beckstead S, Beking D, et al. Treatment of chronic hepatitis C infection among current and former drug users within a multidisciplinary treatment model at a community health centre. Can J Gastroenterol 2012; (27)4: 217-223.
19. Charlebois A, Lee L, Cooper E, et al. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. J Viral Hepat 2012; 19(12): 836-842.
20. Seidenberg A, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis 2013, 13(9): 1471-2334.
21. Litwin AH, Kunins HV, Berg KM, et al. Hepatitis C management by addiction medicine physicians: results from a national survey. J Subst Abuse Treat 2007; 33(1): 99-105.
22. Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment - Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology 2010; 52(3): 1124-1133.
23. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. New Engl J Med 2011; 364(23): 2199-2207.
24. Khatri K, Haddad M, Anderson D. Project ECHO: replicating a novel model to enhance access to hepatitis C care in a community health center. J Health Care for the Poor & Underserved 2013; 24(2): 850-858.
25. Jack K, Willott S, Manners J, et al. Clinical trial: a primary care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 2009; 29(1): 38-45.
26. Wilkie BJ. Identifying and managing hepatitis C in the community. Primary Health Care 2013; 23(4): 22-25.
27. Allen SA, Spaulding AC, Osei AM, et al. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003; 138(3): 187-190.
28. Farley J, Vasdev S, Fischer B, et al. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health 2005; 95(10): 1737-1739.
29. Remy AJ. [Hepatitis C in prison settings: screening and therapy are improving. Comparative survey between 2000 and 2003]. La Presse Medicale 2006; 35(9): 1249-1254. [in French].
30. Gerlich MG, Frick U, Pirktl L, Uchtenhagen A. Detection and treatment of hiv and hepatitis virus infections in Swiss correctional facilities. Int J Public Health 2008; 53: 268-271.
31. Rossaro L, Tran TP, Ransibrahmanakul K, et al. Hepatitis C videoconferencing: the impact on continuing medical education for rural healthcare providers. Telemed J E Health 2007; 13(3): 269-277.
32. National Institute for Health and Clinical Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C. NICE technology appraisal guidance 252. 2012. http://www.nice.org.uk/nicemedia/live/13717/58912/58912.pdf (accessed 3 Nov 2013).
33. National Institute for Health and Clinical Excellence. Boceprevir for the treatment of genotype 1 chronic hepatitis C. NICE technology appraisal guidance 253. 2012. http://www.nice.org.uk/nicemedia/live/13718/58913/58913.pdf (accessed 3 Nov 2013).
34. Department of Health. Implementing care closer to home: Convenient quality care for patients. Part 3 The accreditation of GPs and Pharmacists with Special Interests. London: DOH, 2007.